# Connect Biopharma Connect Biopharma is an Asset Manager based in San Diego, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** San Diego, United States - **Region:** North America - **Address:** San Diego, CA, United States - **Founded:** 2012 - **Assets under management:** Undisclosed - **Website:** connectbiopharm.com ## Regulatory record - **Reports private funds:** No ## About Connect Biopharma launched in 2012 when co-founders Zheng Wei and Wubin Pan pooled immunology research experience from Scripps and Novo Nordisk to build a pipeline around T-cell modulation. The firm incorporated in the Cayman Islands, established labs in Taicang, and opened a US headquarters in San Diego. By the time it listed on Nasdaq in March 2021, it had raised $190 million from the IPO (per Renaissance Capital, 2021) and earlier venture rounds from investors including Lilly Asia Ventures, Qiming Venture Partners, and 3W Capital. The company concentrates on three delivery modalities — oral small molecules, injectable monoclonal antibodies, and topical formulations — across atopic dermatitis, asthma, ulcerative colitis, and eosinophilic esophagitis. Its lead asset, rademikibart, completed Phase 2 trials for atopic dermatitis and was licensed to Simcere Pharmaceutical Group for development and commercialization in Greater China. A second program, icanbelimod, targets sphingosine-1-phosphate receptor 1 in ulcerative colitis and reached Phase 2 enrollment milestones in 2022. The pipeline also included a topical JAK inhibitor, CBP-174, though development priority shifted after broader JAK-class safety concerns emerged (per the firm's Form 20-F, 2022). The Simcere partnership provides milestone payments and royalties, creating a partial non-dilutive funding stream for the US-based Phase 3 program. As a publicly traded clinical-stage biotech with no marketed products, Connect Biopharma manages a lean R&D organization rather than a large commercial infrastructure. The Taicang facility houses discovery and preclinical development, while San Diego runs clinical operations and regulatory strategy. The company made a key leadership move in January 2024, appointing Barry Quart, former CEO of Heron Therapeutics, to its board of directors, signaling deeper US commercialization expertise. Earlier, in September 2022, Connect Biopharma completed a registered direct offering that raised approximately $15 million to extend its cash runway (per the firm, 2022). No dedicated philanthropic or operating-company vehicles sit alongside the listed entity. Connect Biopharma operates a structurally distinct risk model: a Cayman-incorporated, Nasdaq-listed biotech whose core discovery engine and majority shareholder base remain in China, while the clinical pipeline advances toward US and European regulatory endpoints. This split-nation architecture — a common feature of China-US biotech listings like Zai Lab or I-Mab — creates a regulatory and geopolitical complexity that sets it apart from fully US-domiciled immunology peers. The Simcere license for rademikibart further layers the structure, with Greater China economics flowing through a regional partner while Connect retains Western market rights and global data generation responsibilities. ## Sectors - Digital Health - Healthcare Services ## People - Zheng Wei — Co-Founder and CEO - Wubin Pan — Co-Founder and President ## Questions ### What is the clinical-stage status and target indication for Connect Biopharma's lead asset? The lead asset, rademikibart (formerly CBP-201), is a monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα). It completed Phase 2 clinical trials for moderate-to-severe atopic dermatitis, demonstrating potential differentiation from existing biologics. Connect Biopharma is advancing rademikibart toward Phase 3 trials in the United States for atopic dermatitis, while its licensed partner Simcere handles Greater China development and commercialization (per the firm's investor presentations, 2022). ### How does Connect Biopharma fund its operations without a marketed product revenue stream? Connect Biopharma relies on a mix of equity capital markets access, licensing milestone payments, and, historically, venture capital. The March 2021 Nasdaq IPO raised $190 million in gross proceeds (per Renaissance Capital, 2021), and a registered direct offering in September 2022 added approximately $15 million (per the firm, 2022). The Simcere licensing deal for rademikibart in Greater China provides upfront, milestone-based, and royalty-driven non-dilutive funding, though disclosed specific amounts remain limited. ### What is the significance of Connect Biopharma's dual-country R&D structure? Connect Biopharma maintains discovery and preclinical operations in Taicang, China, alongside clinical development and regulatory headquarters in San Diego. This structure allows the firm to access China-based talent and lower-cost discovery infrastructure while running US-standard clinical trials for regulatory submissions to the FDA and EMA. The model introduces regulatory complexity — subject to both CFIUS scrutiny and China's human genetic resources regulations — that differs from single-jurisdiction biotech competitors. ### Who are Connect Biopharma's key co-founders and what is their scientific background? Zheng Wei, CEO, and Wubin Pan, President, co-founded Connect Biopharma in 2012. Wei previously held research roles at The Scripps Research Institute focusing on immunology and antibody discovery. Pan worked at Novo Nordisk and later at Crown Bioscience, building expertise in preclinical pharmacology and translational medicine. This pairing of antibody discovery experience and translational development experience shaped the company's initial focus on T-cell modulation in inflammatory diseases. ### Which therapeutic modalities does Connect Biopharma prioritize in its pipeline? Connect Biopharma's disclosed pipeline spans three delivery modalities: injectable monoclonal antibodies (led by rademikibart), oral small-molecule modulators (led by icanbelimod, a S1P1 receptor modulator for ulcerative colitis), and topical formulations. The topical JAK inhibitor program, CBP-174, was deprioritized following heightened regulatory scrutiny of the JAK inhibitor class (per the firm's 2022 20-F filing), shifting capital toward the injectable and oral programs. ## Related profiles - [AGENUS INC](https://altss.com/profile/agenus-inc) - [Spanish Mountain Gold](https://altss.com/profile/spanish-mountain-gold-ltd) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/connect-biopharma-holdings-ltd Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology